{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:03:31Z","timestamp":1790863411127,"version":"4.1.0"},"reference-count":0,"publisher":"BioExcel","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>The authors wish to make the following corrections to their article: Manunta M, Bruno GM, Ferrantelli A, Ramirez RF, Nardi F. SGLT2 inhibitor role in cardio-metabolic-renal diseases: a narrative review of recent evidence and their pharmacological, clinical and economic implications. Drugs Context. 2026;15:2026-1-1. https:\/\/doi.org\/10.7573\/dic.2026-1-1<\/jats:p>","DOI":"10.7573\/dic.2026-8-5","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:34:40Z","timestamp":1790861680000},"page":"1","source":"Crossref","is-referenced-by-count":0,"title":["Corrigendum: SGLT2 inhibitor role in cardio-metabolicrenal diseases: a narrative review of recent evidence and their pharmacological, clinical and economic implications"],"prefix":"10.7573","author":[{"given":"Mario","family":"Manunta","sequence":"first","affiliation":[{"name":"Centro Salus, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo Matteo","family":"Bruno","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00s6t1f81","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Pavia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Ferrantelli","sequence":"additional","affiliation":[{"name":"ARNAS Civic Hospital, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramiro Francesco","family":"Ramirez","sequence":"additional","affiliation":[{"name":"Content Ed Net srl, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Nardi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01jj26143","id-type":"ROR","asserted-by":"publisher"}],"name":"Ospedale di Santo Spirito"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10047","published-online":{"date-parts":[[2026,10,1]]},"container-title":["Drugs in Context"],"original-title":[],"link":[{"URL":"https:\/\/www.drugsincontext.com\/wp-content\/uploads\/2026\/10\/dic-2026-8-5.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:36:04Z","timestamp":1790861764000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.drugsincontext.com\/corrigendum-sglt2-inhibitor-role-in-cardio-metabolic-renal-diseases-a-narrative-review-of-recent-evidence-and-their-pharmacological-clinical-and-economic-implications"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":0,"URL":"https:\/\/doi.org\/10.7573\/dic.2026-8-5","relation":{},"ISSN":["1740-4398","1740-4398"],"issn-type":[{"value":"1740-4398","type":"print"},{"value":"1740-4398","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"article-number":"dic.2026-8-5"}}